Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.72 |
| ▸ | TNF | P01375 | 7/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | MUSK | O15146 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | STK10 | O94804 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687473 | 0.91 | TNF (0.74) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6688966 | 0.90 | TNF (0.67) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4686509 | 0.89 | TNF (0.76) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4689572 | 0.89 | MAPK14 (0.72) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4686520 | 0.89 | TNF (0.76) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4686661 | 0.89 | MAPK14 (0.74) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4693412 | 0.89 | MAPK14 (0.74) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4688973 | 0.88 | MAPK14 (0.73) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4686562 | 0.87 | MAPK14 (0.72) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4686541 | 0.85 | MAPK14 (0.76) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | claimed |
| US-7041669-B2 | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7041669-B2 | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1480973-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003072569-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | IL1A, IL1B, XDH | MAPK14 3000/4885TNF 10/4885MAPK13 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.